What exactly are immunoglobulins, why do we need them and why are they reduced in some people by the so-called B-cell depleters Ocrelizumab and Ofatumumab? Do you always have to take action with low immunoglobulin levels, or only when severe infections are added? When is an infection “severe”?
What can be done? What alternatives are there to end a secondary immunodeficiency? What about extended dosage intervals, i.e., taking the active ingredients less often?
Prof. Mathias Mäurer answers all these questions in the current MS-Docblog video. Also see and Report 1 and Report 2 on MS-Docblog as well as our Report on amsel.de
Please consider using the automated translation of YouTube. You can activate this function by clicking on the settings symbol and choosing subtitles.
